Jeronselvein, a company specializing in the production of prescription drugs, announced on the 19th that it participated as a speaker at the "2025 Korean Society for Stem Cell Therapy Spring Academic Conference," where it delivered a lecture on the clinical efficacy of "Selvein Injection."
The "2025 Korean Society for Stem Cell Therapy Spring Academic Conference," held by the Korean Society for Stem Cell Therapy on May 18, focused on sharing a wide range of clinical experiences, including the latest cell therapy strategies that can be applied directly in clinical settings, nutrition therapy combined with regenerative medicine, musculoskeletal pain management, and cosmetic laser procedures.
Through lectures on stem cell procedure experiences and clinical cases, ranging from simple stem cell procedures to those utilizing fat harvesting and bone marrow tissue, Jeronselvein shared key data demonstrating the clinical efficacy of "Selvein Injection" in skin damage recovery, inflammation suppression, and promotion of tissue regeneration.
At this academic conference, Jeronselvein CEO Kim Deokgyu gave a presentation titled "Advancing Regenerative Therapy with Low-Temperature Synthesized PDRN," discussing the latest insights on polydeoxyribonucleotide (PDRN) and its relationship with stem cells. The company also set up a booth at the conference to introduce the efficacy and product competitiveness of "Selvein Injection" to medical professionals.
Kim Deokgyu, CEO of Jeronselvein, stated, "PDRN is highly effective when used in combination with stem cells, autologous platelet-rich plasma (PRP), and autologous blood (PRF), which is why it is widely used in plastic surgery and stem cell fields."
He added, "It was a very meaningful opportunity to introduce our core technologies to domestic and international medical professionals who have a strong interest in stem cells and anti-aging. Based on various clinical data in the future, we plan to accelerate our entry into the global regenerative medicine market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
